D
Demetrix
Manufactures natural medicines using synthesis biology
About Demetrix
Demetrix is a biotechnology startup that specializes in the research and production of rare cannabinoids through advanced fermentation technology. The company operates in the health, wellness, and beauty markets, providing scientifically-backed ingredients for personal care applications. Demetrix's primary clients are businesses seeking high-quality, consistent, and sustainable cannabinoid ingredients for their products.
The company's business model revolves around the production and sale of these rare cannabinoids. They use a cutting-edge fermentation process, which is more sustainable, cost-effective, and capable of producing higher purity cannabinoids than traditional agricultural methods. This process does not involve the use of plant material, making it a unique selling point for the company.
Demetrix's revenue is generated through the sale of these ingredients to businesses in the health, wellness, and beauty sectors. The company prides itself on its ability to provide a consistent, high-purity supply of ingredients, which is crucial for businesses that require reliable and consistent sources for their products.
The company's name, Demetrix, is inspired by Demeter, the Greek goddess of the harvest, symbolizing the company's commitment to nature and sustainability. The team at Demetrix is composed of industry-leading experts, ensuring that their products meet the highest standards of quality and safety.
In summary, Demetrix is a biotech startup that uses advanced fermentation technology to produce rare cannabinoids for use in the health, wellness, and beauty sectors. They offer a sustainable, cost-effective, and high-quality alternative to traditional cannabinoid production methods.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Berkeley, United States
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 79.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jul 2019 | $50M | $200M | Tuatara Capital · Li Ka-shing · Horizons Ventures | — |
| SEEDOther financing | Sep 2017 | $4M | $16M | Horizons Ventures | — |
Growth signals
Latest recorded traffic for Demetrix is 400 monthly website visits, down 63.6% over the last three months. Demetrix's team grew 5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A2 investors entered at this stage
- TCTuatara Capital
Li Ka-shing
Other known investors1 additional known investor
University of California, Berkeley
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Demetrix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Demetrix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








